insulin degludec vs SHR-3167

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin degludec · Tresiba

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT00982644 · Phase 3 · completed

The trial was randomized and actively controlled, with 1,030 participants, but it was not blinded and its primary endpoint was the surrogate measure of change in HbA1c rather than a hard clinical outcome. HbA1c changed by -1.06% with insulin degludec versus -1.19% with insulin glargine, but no statistical comparison is reported, so whether the primary endpoint was met is unclear.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52); Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes (Week 0 to Week 104 + 7 days follow up); Extension Trial (Primary Endpoint): Rate of Treatment Emergent Adverse Events (AEs) (Week 0 to Week 104 + 7 days of follow up): Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97) (unclear)

Result source: NCT00982644

SHR-3167

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06688123 · Phase 2 · completed

The study randomized 275 adults with type 2 diabetes to once-weekly SHR-3167 (two titration schemes) or daily insulin glargine in an open-label, treat-to-target design. Its primary endpoint was change in HbA1c at week 20, a regulator-accepted measure in type 2 diabetes. Hengrui reports HbA1c reductions similar to glargine (differences -0.02% and -0.14%, with both confidence intervals crossing zero), but neither the registry nor the company states a non-inferiority margin, so whether the primary comparison was met cannot be called. The figures are company-reported and not peer reviewed.

Company release of an EASD 2026 late-breaking abstract; not peer reviewed and not posted on the registry.

Next expected readout: December 2026 · NCT07472725 (registry estimate)

Reported efficacy

Change from baseline to week 20 in HbA1c (HemoglobinA1c) (Week 0 to week 20.): Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated.

Result source: NCT06688123

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin degludecSHR-3167
HbA1c, change-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
—Trial running · NCT07913061
Body weight, change (kg)1.2 vs 3vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 2.9 vs -1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
—Trial running · NCT07913061
HbA1c below 7%75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116—Trial running · NCT07913061
Fasting plasma glucose, change-3.9 vs -3.7vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
—Trial running · NCT07913061
3-point MACE (% with event)—Not posted · NCT05802862—Trial running · NCT07913061

HbA1c, change

insulin degludec
-1.1% vs -1.2%vs IGlaronce daily · wk 52 · n 773NCT00982644
22 other results
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · primary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · primary NCT02607306
  • -1.4% vs -1.6% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -1.7% vs -1.2% wk 26 · n 341 · Phase 3 · primary NCT03172494
  • -1.2% vs -1.2% wk 26 · n 167 · Phase 3 · primary NCT03172494
  • -1.9% vs -1.1% wk 26 · n 289 · Phase 3 · primary NCT03175120
  • -1.5% vs -1.4% BID · wk 26 · n 359 · Phase 3 · primary NCT02762578
  • -0.1% vs -0.1% wk 16 · n 544 · Phase 3 · primary NCT03268005
  • -1.9% vs -0.7% wk 26 · n 105 · Phase 3 · primary NCT02911948
  • -1.5% vs -1.5% wk 26 · n 244 · Phase 3 · primary NCT02420262
  • -1.8% vs -1.1% wk 26 · n 278 · Phase 3 · primary NCT01952145
  • -1.3% vs -0.4% wk 26 · n 292 · Phase 3 · primary NCT01676116
  • -0.6% vs -0.5% wk 16 · n 143 · Phase 3 · primary NCT04588259
  • -0.1% vs -0.1% wk 16 · n 138 · Phase 3 · primary NCT01570751
  • -1.1% vs -1.1% twice daily · wk 4.14 · n 121 · Phase 3 · primary NCT02648217
  • -0.9% vs -0.8% wk 104 · n 2431 · Phase 3 · secondary NCT01959529
  • -0.9% vs -1.1% once daily · wk 104 · n 773 · Phase 3 · secondary NCT00982644
  • -0.5% vs -0.5% wk 88 · n 694 · Phase 3 · secondary NCT03078478
  • -2.4% vs -1.8% wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -1.8% vs -1.8% wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -2.0% vs -1.7% wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -0.5% vs 0% once weekly · wk 26 · n 40 · Phase 4 · primary NCT04538352
SHR-3167
—Trial running · NCT07913061

Body weight, change (kg)

insulin degludec
1.2 vs 3vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • 2.9 vs 1.7 wk 88 · n 701 · Phase 3 · secondary NCT03078478
  • 2.9 vs -1 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • 4.1 vs -1 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • 2.3 vs 2.8 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 0.2 vs -2.5 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • 0.5 vs 2.2 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -1.4 vs 1.8 wk 26 · n 278 · Phase 3 · secondary NCT01952145
  • 1.2 vs 1.1 wk 16 · n 522 · Phase 3 · secondary NCT03268005
  • 1.3 vs -2.5 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -0.7 vs 0.5 wk 26 · n 288 · Phase 3 · secondary NCT03175120
  • 2.8 vs 2.2 BID · wk 26 · n 359 · Phase 3 · secondary NCT02762578
  • -0.7 vs 0.7 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • -0.9 vs 2.6 wk 26 · n 244 · Phase 3 · secondary NCT02420262
  • 2 vs -0.8 wk 26 · n 292 · Phase 3 · secondary NCT01676116
  • -8.6 vs 1.4 once weekly · wk 26 · n 40 · Phase 4 · secondary NCT04538352
SHR-3167
—Trial running · NCT07913061

HbA1c below 7%

insulin degludec
75.3% vs 35.6%vs Liraglutide or Exenatidewk 26 · n 292NCT01676116
SHR-3167
—Trial running · NCT07913061

Fasting plasma glucose, change

insulin degludec
-3.9 vs -3.7vs Insulin Glarginewk 104 · n 506NCT02501161
15 other results
  • -2.0 vs -1.4 wk 88 · n 685 · Phase 3 · secondary NCT03078478
  • -4.1 vs -2.6 wk 52 · n 275 · Phase 3 · secondary NCT02607306
  • -4.0 vs -2.6 wk 52 · n 271 · Phase 3 · secondary NCT02607306
  • -3.0 vs -3.0 wk 26 · n 290 · Phase 3 · secondary NCT04795531
  • -3.6 vs -1.9 wk 26 · n 341 · Phase 3 · secondary NCT03172494
  • -4.0 vs -3.8 wk 26 · n 506 · Phase 3 · secondary NCT02501161
  • -3.0 vs -0.6 wk 26 · n 285 · Phase 3 · secondary NCT01676116
  • 0.6 vs 0.7 wk 16 · n 533 · Phase 3 · secondary NCT03268005
  • -3.5 vs -1.9 wk 26 · n 167 · Phase 3 · secondary NCT03172494
  • -3.6 vs -2.8 wk 26 · n 289 · Phase 3 · secondary NCT03175120
  • -3.0 vs -1.6 BID · wk 26 · n 354 · Phase 3 · secondary NCT02762578
  • -2.8 vs -2.3 wk 26 · n 105 · Phase 3 · secondary NCT02911948
  • 0.4 vs 0.2 wk 16 · n 143 · Phase 3 · secondary NCT04588259
  • -0.8 vs 0 wk 16 · n 128 · Phase 3 · secondary NCT01570751
  • -2 vs -4.4 twice daily · wk 4.14 · n 115 · Phase 3 · secondary NCT02648217
SHR-3167
—Trial running · NCT07913061

3-point MACE (% with event)

insulin degludec
—Not posted · NCT05802862
SHR-3167
—Trial running · NCT07913061
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

SHR-3167
Change in HbA1c from baseline to week 20 (primary): least-squares mean -1.37% (SHR-3167 group A, titration step 2 mg) and -1.49% (group B, titration step 1.5 mg) vs -1.35% with insulin glargine U100; differences -0.02% (95% CI -0.20 to 0.16) and -0.14% (95% CI -0.32 to 0.05); 275 randomized. No non-inferiority margin is stated. NCT06688123 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin degludec: 4 of 4 rows · SHR-3167: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin degludec
Dropout rate
21.5%once dailya
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
2%
NCT01959529 · Phase 3
0%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
10.9%
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
2.7%
NCT04795531 · Phase 3 · registry result, not featured evidence
6.7%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
2.7%
NCT03268005 · Phase 3 · registry result, not featured evidence
4.3%
NCT02501161 · Phase 3 · registry result, not featured evidence
2.2%
NCT02906917 · Phase 3 · registry result, not featured evidence
8.5%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
7.6%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
0%
NCT02911948 · Phase 3 · registry result, not featured evidence
4.8%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.2%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
7.6%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
2.9%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
10.1%
NCT01952145 · Phase 3 · registry result, not featured evidence
5.5%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
2.6%once dailya
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
0%
NCT01959529 · Phase 3
—once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
—
NCT03336528 · Phase 4 · registry result, not featured evidence
—
NCT04588259 · Phase 3 · registry result, not featured evidence
—
NCT04795531 · Phase 3 · registry result, not featured evidence
0.6%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
1.4%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
0.7%
NCT03175120 · Phase 3 · registry result, not featured evidence
—
NCT03078478 · Phase 3 · registry result, not featured evidence
—
NCT03268005 · Phase 3 · registry result, not featured evidence
0.4%
NCT02501161 · Phase 3 · registry result, not featured evidence
0.4%
NCT02906917 · Phase 3 · registry result, not featured evidence
2.2%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
—
NCT02911948 · Phase 3 · registry result, not featured evidence
—
NCT02773368 · Phase 3 · registry result, not featured evidence
0.3%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
0.4%
NCT02420262 · Phase 3 · registry result, not featured evidence
0%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
1%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
2.9%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
3.2%
NCT01952145 · Phase 3 · registry result, not featured evidence
0.3%Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
—
NCT01570751 · Phase 3 · registry result, not featured evidence
Serious AEs
15.1%once dailya
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 25 more results
38.6%
NCT01959529 · Phase 3
22.5%once weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
3.7%
NCT03336528 · Phase 4 · registry result, not featured evidence
6.7%
NCT04588259 · Phase 3 · registry result, not featured evidence
5.1%
NCT04795531 · Phase 3 · registry result, not featured evidence
4%Insulin Degludec
NCT03172494 · Phase 3 · registry result, not featured evidence
3.9%Insulin Degludec/Liraglutide
NCT03172494 · Phase 3 · registry result, not featured evidence
4.3%
NCT03175120 · Phase 3 · registry result, not featured evidence
20.8%
NCT03078478 · Phase 3 · registry result, not featured evidence
7%
NCT03268005 · Phase 3 · registry result, not featured evidence
11.9%
NCT02501161 · Phase 3 · registry result, not featured evidence
6.8%
NCT02906917 · Phase 3 · registry result, not featured evidence
4.8%Insulin Degludec
NCT02607306 · Phase 3 · registry result, not featured evidence
6.2%Insulin Degludec/Liraglutide
NCT02607306 · Phase 3 · registry result, not featured evidence
2.9%
NCT02911948 · Phase 3 · registry result, not featured evidence
2.9%
NCT02773368 · Phase 3 · registry result, not featured evidence
4.4%BID
NCT02762578 · Phase 3 · registry result, not featured evidence
4.8%
NCT02420262 · Phase 3 · registry result, not featured evidence
3.8%twice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
6.7%IDegLira
NCT02298192 · Phase 3 · registry result, not featured evidence
3.3%IDegLira (1WT)
NCT02298192 · Phase 3 · registry result, not featured evidence
1.8%
NCT01952145 · Phase 3 · registry result, not featured evidence
—Insulin Degludec/Liraglutide + Ora
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
3.1%Insulin Degludec/Liraglutide +OADs
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
2.9%
NCT01570751 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
once dailya
nasopharyngitis 23.9%
headache 13.8%
diarrhoea 10.8%
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 23 more results
once weekly
pain 17.5%
upper respiratory infection 0%
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
emergency room visit for bilateral knee pain 1.2%
emergency room visit for congestive heart failure 1.2%
emergency room visit for wound infection 1.2%
NCT03336528 · Phase 4 · registry result, not featured evidence
diabetic retinopathy 14.7%
hyperlipidaemia 14%
upper respiratory tract infection 9.3%
NCT04588259 · Phase 3 · registry result, not featured evidence
covid-19 4.8%
influenza 3.1%
diabetic retinopathy 2%
NCT04795531 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.7%
nasopharyngitis 5.1%
diabetic retinopathy 3.4%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 18.4%
diabetic retinopathy 7.8%
lipase increased 7.5%
NCT03172494 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 12.6%
lipase increased 12%
diabetic retinopathy 11.6%
NCT03175120 · Phase 3 · registry result, not featured evidence
nasopharyngitis 19%
upper respiratory tract infection 18.1%
diarrhoea 9%
NCT03078478 · Phase 3 · registry result, not featured evidence
nasopharyngitis 5.9%
NCT03268005 · Phase 3 · registry result, not featured evidence
headache 11.5%
nasopharyngitis 11.3%
diarrhoea 7.7%
NCT02501161 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.2%
back pain 6%
NCT02906917 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 33.6%
weight increased 7%
pharyngitis 5.5%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 38.5%
constipation 9.8%
diabetic retinopathy 6.2%
NCT02607306 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20%
diabetic retinopathy 16.2%
diarrhoea 14.3%
NCT02911948 · Phase 3 · registry result, not featured evidence
headache 8.6%
viral upper respiratory tract infection 7.7%
lipase increased 5.7%
NCT02773368 · Phase 3 · registry result, not featured evidence
BID
upper respiratory tract infection 21.1%
diabetic retinopathy 10%
viral upper respiratory tract infection 2.5%
NCT02762578 · Phase 3 · registry result, not featured evidence
nausea 11.1%
influenza 7.1%
diarrhoea 6.3%
NCT02420262 · Phase 3 · registry result, not featured evidence
twice daily
blood glucose decreased 35.4%
upper respiratory tract infection 6.2%
pyrexia 3.1%
NCT02648217 · Phase 3 · registry result, not featured evidence
nausea 5.2%
nasopharyngitis 4.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nasopharyngitis 6.2%
nausea 5.3%
NCT02298192 · Phase 3 · registry result, not featured evidence
nausea 9.4%
diarrhoea 7.2%
vomiting 5%
NCT01952145 · Phase 3 · registry result, not featured evidence
lipase increased 10%
headache 9.3%
nasopharyngitis 8.9%
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 1.4%
NCT01570751 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin degludec

HbA1c -1.06% (n=773) vs -1.19% (n=257) IGlar @ 52wkonce daily
absolute change · percentage points
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 22 more results
-0.95% (n=773) vs -1.11% (n=257) IGlar @ 104wkonce daily
NCT00982644 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.86% (n=2431) vs -0.84% (n=2404) Insulin Glargine @ 104wk
NCT01959529 · Phase 3
-0.5% (n=40) vs 0% (n=20) Insulin @ 26wkonce weekly
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
-0.57% (n=143) vs -0.54% (n=145) NovoRapid @ 16wk
NCT04588259 · Phase 3 · registry result, not featured evidence
-1.36% (n=294) vs -1.57% (n=294) Insulin Icodec @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
-1.71% (n=341) vs -1.16% (n=151) Liraglutide @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-1.2% (n=167) vs -1.16% (n=151) Liraglutide @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-1.93% (n=289) vs -1.06% (n=138) Insulin Degludec @ 26wk
NCT03175120 · Phase 3 · registry result, not featured evidence
-0.54% (n=694) vs -0.46% (n=700) Insulin Glargine @ 88wk
NCT03078478 · Phase 3 · registry result, not featured evidence
-0.15% (n=544) vs -0.09% (n=539) NovoRapid @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
-1.99% (n=506) vs -1.69% (n=506) Insulin Glargine @ 26wk
NCT02501161 · Phase 3 · registry result, not featured evidence
-2.42% (n=275) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.8% (n=271) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-2.42% (n=275) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.8% (n=271) vs -1.8% (n=273) Liraglutide @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-1.95% (n=105) vs -0.65% (n=105) Insulin Degludec @ 26wk
NCT02911948 · Phase 3 · registry result, not featured evidence
-1.48% (n=359) vs -1.4% (n=182) BIAsp 30 @ 26wkBID
NCT02762578 · Phase 3 · registry result, not featured evidence
-1.48% (n=244) vs -1.46% (n=245) IGlar + IAsp @ 26wk
NCT02420262 · Phase 3 · registry result, not featured evidence
-1.11% (n=121) vs -1.13% (n=124) Biphasic Insulin Aspart 30 @ 4.14wktwice daily
NCT02648217 · Phase 3 · registry result, not featured evidence
-1.81% (n=278) vs -1.13% (n=279) Insulin Glargine (IGlar) @ 26wk
NCT01952145 · Phase 3 · registry result, not featured evidence
-1.32% (n=292) vs -0.37% (n=146) Liraglutide or Exenatide @ 26wk
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
-0.1% (n=138) vs -0.1% (n=138) IGlar @ 16wk
NCT01570751 · Phase 3 · registry result, not featured evidence
Time to First MACE 8.5% (n=3818) vs 9.3% (n=3819) Insulin Glargine
event count · % of participants
First EAC-confirmed MACE
NCT01959529 · Phase 3 · converted to % from 325 Participants as posted
Non-fatal MI 3.7% (n=3818) vs 4.3% (n=3819) Insulin Glargine
event count · % of participants
Myocardial infarction (non-fatal)
NCT01959529 · Phase 3 · converted to % from 143 Participants as posted
Stroke 1.8% (n=3818) vs 1.9% (n=3819) Insulin Glargine
responder rate · % of participants
Stroke (non-fatal)
NCT01959529 · Phase 3 · converted to % from 68 Participants as posted
CV Death 3% (n=3818) vs 3.1% (n=3819) Insulin Glargine
responder rate · % of participants
Cardiovascular death
NCT01959529 · Phase 3 · converted to % from 114 Participants as posted
Hypoglycemia Episodes Level 3 280 vs 472 Insulin Glargine count
event count · count
NCT01959529 · Phase 3
show 2 more results
2 vs 0 Insulin Icodec count @ 31wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0 vs 0 Insulin Icodec count @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
Hypoglycemia Event Incidence 4.9% (n=3818) vs 6.6% (n=3819) Insulin Glargine
event rate · % of participants
NCT01959529 · Phase 3 · converted to % from 187 Participants as posted
Weight -8.6 vs 1.4 Insulin kg @ 26wkonce weekly
absolute change · kg
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
show 15 more results
2.32 vs 2.77 Insulin Icodec kg @ 26wk
NCT04795531 · Phase 3 · registry result, not featured evidence
0.2 vs -2.5 Liraglutide kg @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
1.3 vs -2.5 Liraglutide kg @ 26wk
NCT03172494 · Phase 3 · registry result, not featured evidence
-0.7 vs 0.5 Insulin Degludec kg @ 26wk
NCT03175120 · Phase 3 · registry result, not featured evidence
2.9 vs 1.7 Insulin Glargine kg @ 88wk
NCT03078478 · Phase 3 · registry result, not featured evidence
1.19 vs 1.12 NovoRapid kg @ 16wk
NCT03268005 · Phase 3 · registry result, not featured evidence
0.5 vs 2.2 Insulin Glargine kg @ 26wk
NCT02501161 · Phase 3 · registry result, not featured evidence
1.2 vs 3 Insulin Glargine kg @ 104wk
NCT02501161 · Phase 3 · registry result, not featured evidence
2.9 vs -1 Liraglutide kg @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
4.1 vs -1 Liraglutide kg @ 52wk
NCT02607306 · Phase 3 · registry result, not featured evidence
-0.7 vs 0.7 Insulin Degludec kg @ 26wk
NCT02911948 · Phase 3 · registry result, not featured evidence
2.82 vs 2.21 BIAsp 30 kg @ 26wkBID
NCT02762578 · Phase 3 · registry result, not featured evidence
-0.93 vs 2.64 IGlar + IAsp kg @ 26wk
NCT02420262 · Phase 3 · registry result, not featured evidence
-1.4 vs 1.8 Insulin Glargine (IGlar) kg @ 26wk
NCT01952145 · Phase 3 · registry result, not featured evidence
2 vs -0.8 Liraglutide or Exenatide kg @ 26wk
NCT01676116 · Phase 3 · registry result, not featured evidence · combination
HbA1c -0.5 vs 0 Insulin actual mean A1C change @ 26wkonce weekly
absolute change · actual mean A1C change
NCT04538352 · Phase 4 · registry result, not featured evidence · combination
Daily Glucose mg/dL 9.98 vs 10.03 Glargine mmol/L @ 1wk
absolute value · mmol/L
Day 1 up to Day 10
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 179.75 mg/dL as posted
Daily Glucose mg/dL 8.71 vs 7.94 Glargine mmol/L @ 4wk
absolute value · mmol/L
Day after discharge up to the 4 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 157 mg/dL as posted
Daily Glucose mg/dL 8.25 vs 7.43 Glargine mmol/L @ 12wk
absolute value · mmol/L
4 week post-discharge up to the 12 week post-discharge study visit
NCT03336528 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 148.7 mg/dL as posted

+ 111 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin degludec's landscape · SHR-3167's landscape